The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Yes, nice quarter. Maybe I could start some P&L questions. Scott, gross margin was a touch light in the quarter. Just maybe walk us
through how you get back up to the 76%, 77% guidance through the back part of the year. What gives you the confidence?
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Great. And while we're on the P&L, I'll use another here. The accounting charge that was a benefit this quarter, I didn't hear what it
was related to. If you don't mind, just what it's -- letting us know what it's tied to, appreciate it.
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Is there any specific deals you can talk to? Or is it just the overall portfolio?
Question: Travis Lee Steed - Barclays Bank PLC, Research Division - Analyst
: I guess one longer-term question on margins. You're spending a lot today on R&D and SG&A but also have a lot of investments in
front of you. So just curious how you think, longer term, how you balance the spending versus margin expansion.
Question: Travis Lee Steed - Barclays Bank PLC, Research Division - Analyst
: All right. That's helpful. On the international business, I don't know if you've mentioned any update on China and how that's going.
I noticed Medtronic followed a study today and TAVR for their device in China. So curious if there's any update on China. And are
you looking at other markets to move into as well longer term?
|